版本:
中国

BRIEF-Medicenna's Immunotherapy phase 2B trial underway using Brainlab drug delivery technology

June 8 Medicenna Therapeutics Corp

* Medicenna's Immunotherapy phase 2B trial underway using Brainlab drug delivery technology

* Medicenna Therapeutics - current phase 2B clinical trial plans to enroll 43 adult patients with RGB at leading brain cancer centers in United States Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐